Drug intelligence / Profile preview

buprenorphine + bupivacaine

Development stage: Preclinical
Lead developer: Reckitt
Modality: Small Molecules
Administration: Epidural, Perineural, Infiltration

Overview

A combination of buprenorphine, a partial opioid agonist, and bupivacaine, an amide local anesthetic. This combination is primarily used in regional nerve blocks and anesthesia to provide enhanced and prolonged analgesia. Studies have shown that adding buprenorphine to bupivacaine can significantly extend the duration of pain relief compared to bupivacaine alone, with analgesic effects lasting up to 96 hours in some cases versus 24-72 hours with bupivacaine alone.

Targets

NOP (Nociceptin/orphanin FQ peptide receptor)NaV (Voltage-gated sodium channels)MOR (Mu opioid receptor)DOR (Opioid Receptor Delta 1)KOR (Kappa opioid receptor)

Beyond the preview

Go deeper on buprenorphine + bupivacaine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on buprenorphine + bupivacaine.

Explore the full profile